ReBioLup is an international prospective endeavour conducted within the frame of the Lupus Nephritis Trials Network. ReBioLup is endorsed by the SLEuro. The main objective of this randomised trial is to evaluate whether therapeutic decisions steered by the results of a per-protocol repeat kidney biopsy contribute to an increased proportion of patients who attain complete renal response after two years of immunosuppressive therapy, and deceleration of renal function loss in the long run.
Previous ProjectTaxonomy, Treatment, Targets and Remission (3TR)
